These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30420505)

  • 1. Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4.
    Stewart-Jones GBE; Chuang GY; Xu K; Zhou T; Acharya P; Tsybovsky Y; Ou L; Zhang B; Fernandez-Rodriguez B; Gilardi V; Silacci-Fregni C; Beltramello M; Baxa U; Druz A; Kong WP; Thomas PV; Yang Y; Foulds KE; Todd JP; Wei H; Salazar AM; Scorpio DG; Carragher B; Potter CS; Corti D; Mascola JR; Lanzavecchia A; Kwong PD
    Proc Natl Acad Sci U S A; 2018 Nov; 115(48):12265-12270. PubMed ID: 30420505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
    Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR
    Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of vaccines for parainfluenza virus infections.
    Sato M; Wright PF
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S123-5. PubMed ID: 18820572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.
    Palomo C; Mas V; Thom M; Vázquez M; Cano O; Terrón MC; Luque D; Taylor G; Melero JA
    J Virol; 2016 Jun; 90(11):5485-5498. PubMed ID: 27009962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
    Tao T; Skiadopoulos MH; Durbin AP; Davoodi F; Collins PL; Murphy BR
    Vaccine; 1999 Mar; 17(9-10):1100-8. PubMed ID: 10195620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus.
    Ou L; Chen SJ; Teng IT; Yang L; Zhang B; Zhou T; Biju A; Cheng C; Kong WP; Morano NC; Stancofski ED; Todd JP; Tsybovsky Y; Wang S; Zheng CY; Mascola JR; Shapiro L; Woodward RA; Buchholz UJ; Kwong PD
    PLoS Pathog; 2023 Sep; 19(9):e1011584. PubMed ID: 37738240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
    Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR
    J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
    Tao T; Durbin AP; Whitehead SS; Davoodi F; Collins PL; Murphy BR
    J Virol; 1998 Apr; 72(4):2955-61. PubMed ID: 9525616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone.
    Tao T; Skiadopoulos MH; Davoodi F; Surman SR; Collins PL; Murphy BR
    Vaccine; 2001 Jun; 19(27):3620-31. PubMed ID: 11395195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs.
    Garg R; Latimer L; Gomis S; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2019 Feb; 162():54-60. PubMed ID: 30550799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
    Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses.
    Stewart-Jones GBE; Gorman J; Ou L; Zhang B; Joyce MG; Yang L; Cheng C; Chuang GY; Foulds KE; Kong WP; Olia AS; Sastry M; Shen CH; Todd JP; Tsybovsky Y; Verardi R; Yang Y; Collins PL; Corti D; Lanzavecchia A; Scorpio DG; Mascola JR; Buchholz UJ; Kwong PD
    Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34551978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
    Swanson KA; Settembre EC; Shaw CA; Dey AK; Rappuoli R; Mandl CW; Dormitzer PR; Carfi A
    Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9619-24. PubMed ID: 21586636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.